The treatment of pulmonary arterial hypertension (PAH) is evolving. With the emergence of disease-modifying therapies (DMTs), it is essential that healthcare providers understand their mechanisms of action and are aware of the safety and efficacy data of recently published clinical trials. In this satellite symposium, HCPs will learn how to integrate new treatment strategies using both existing and emerging therapeutic entities. You don’t want to miss this opportunity to enhance your ability to customize a risk-based approach for comprehensive management of your patients with PAH.
Pulmonary Hypertension: Diagnosis, Management, and Updates
Review clinical trial evidence for DMTs then learn how to customize a risk-based approach for comprehensive management of patients with PAH.
Live
Broadcast
1.50 available credits
Information
November 16, 2024
07:00 PM - 08:30 PM CST
Virtual
Share
This live broadcast will start in exactly:
- 0
Day(s)
- 0
Hour(s)
- 0
Minute(s)
- 0
Second(s)
Share
Share
Share this program on:
Details
Presenters
Comments
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Vallerie V. McLaughlin, MD
Kim A. Eagle, MD Endowed Professor of Cardiovascular Medicine
Director, Pulmonary Hypertension Program
University of Michigan Medical School
Ann Arbor, MI
Dr. McLaughlin has reported the following relevant financial relationships with ineligible companies during the past 24 months:
Consulting Fees: Aerami, Aerovate, Altavant, Apollo Therapeutics, Bayer, CVS/Caremark, CorVista, Gossamer Bio, Janssen, Keros, Merck, United Therapeutics, Vertex
Research: Aerovate, Altavant/Enzyvant, Gossamer Bio, Keros, Janssen, Merck/Acceleron, SoniVie
Panelists:
Marc Humbert, MD, PhD
Professor of Respiratory Medicine
Assistance Publique – Hôpitaux de Paris
Université Paris-Saclay
Inserm, France
Dr. Humbert has reported the following relevant financial relationships with ineligible companies during the past 24 months:
Consulting Fees: 35Pharma, Aerovate, AOP Pharma, Chiesi, Ferrer, Gossamer, Janssen, Keros, Liquidia, Merck, Morphic, Novartis, Regeneron, Respira, Roivant, United Therapeutics
Research: Gossamer Bio, Merck
Ryan J. Tedford, MD, FACC, FAHA, FHFSA
Professor of Medicine/Cardiology
Peter C. Gazes Endowed Chair in Heart Failure
Medical University of South Carolina
Charleston, SCDr. Tedford has reported the following relevant financial relationships with ineligible companies during the past 24 months:
Consulting Fees: Abbott, Acorai, Adona, Aria CV, Inc., Acceleron/Merck, Alleviant, Boston Scientific, Cytokinetics, Edwards Lifesciences, Endotronix, Gradient, Medtronic, Morphic Therapeutics, Restore Medical, and United Therapeutics
Research: Abiomed, BioVentrix, NIH
Ownership Interest: Aria CV, Inc.
Reviewers/Content Planners/Authors:- Cindy Davidson has nothing to disclose.
- Prerna Poojary, PhD, has nothing to disclose.
- Kathleen Sheridan, PhD, has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Describe how the mechanisms of action of newer disease-modifying therapies (DMTs) will address the underlying pathology of pulmonary arterial hypertension (PAH)
- Discuss the impact of current standard of care in PAH vs newer DMTs on patient outcomes
- Identify patients who may benefit from treatment with a newer DMT
- Develop a treatment plan that incorporates DMTs at the right time, in the right patient using risk assessment
Target Audience
This activity has been designed to meet the educational needs of cardiologists, pulmonologists, and rheumatologists, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with PAH.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-113-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant from Merck & Co., Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Details
Presenters
Comments
Overview
The treatment of pulmonary arterial hypertension (PAH) is evolving. With the emergence of disease-modifying therapies (DMTs), it is essential that healthcare providers understand their mechanisms of action and are aware of the safety and efficacy data of recently published clinical trials. In this satellite symposium, HCPs will learn how to integrate new treatment strategies using both existing and emerging therapeutic entities. You don’t want to miss this opportunity to enhance your ability to customize a risk-based approach for comprehensive management of your patients with PAH.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Vallerie V. McLaughlin, MD
Kim A. Eagle, MD Endowed Professor of Cardiovascular Medicine
Director, Pulmonary Hypertension Program
University of Michigan Medical School
Ann Arbor, MI
Dr. McLaughlin has reported the following relevant financial relationships with ineligible companies during the past 24 months:
Consulting Fees: Aerami, Aerovate, Altavant, Apollo Therapeutics, Bayer, CVS/Caremark, CorVista, Gossamer Bio, Janssen, Keros, Merck, United Therapeutics, Vertex
Research: Aerovate, Altavant/Enzyvant, Gossamer Bio, Keros, Janssen, Merck/Acceleron, SoniVie
Panelists:
Marc Humbert, MD, PhD
Professor of Respiratory Medicine
Assistance Publique – Hôpitaux de Paris
Université Paris-Saclay
Inserm, France
Dr. Humbert has reported the following relevant financial relationships with ineligible companies during the past 24 months:
Consulting Fees: 35Pharma, Aerovate, AOP Pharma, Chiesi, Ferrer, Gossamer, Janssen, Keros, Liquidia, Merck, Morphic, Novartis, Regeneron, Respira, Roivant, United Therapeutics
Research: Gossamer Bio, Merck
Ryan J. Tedford, MD, FACC, FAHA, FHFSA
Professor of Medicine/Cardiology
Peter C. Gazes Endowed Chair in Heart Failure
Medical University of South Carolina
Charleston, SCDr. Tedford has reported the following relevant financial relationships with ineligible companies during the past 24 months:
Consulting Fees: Abbott, Acorai, Adona, Aria CV, Inc., Acceleron/Merck, Alleviant, Boston Scientific, Cytokinetics, Edwards Lifesciences, Endotronix, Gradient, Medtronic, Morphic Therapeutics, Restore Medical, and United Therapeutics
Research: Abiomed, BioVentrix, NIH
Ownership Interest: Aria CV, Inc.
Reviewers/Content Planners/Authors:- Cindy Davidson has nothing to disclose.
- Prerna Poojary, PhD, has nothing to disclose.
- Kathleen Sheridan, PhD, has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Describe how the mechanisms of action of newer disease-modifying therapies (DMTs) will address the underlying pathology of pulmonary arterial hypertension (PAH)
- Discuss the impact of current standard of care in PAH vs newer DMTs on patient outcomes
- Identify patients who may benefit from treatment with a newer DMT
- Develop a treatment plan that incorporates DMTs at the right time, in the right patient using risk assessment
Target Audience
This activity has been designed to meet the educational needs of cardiologists, pulmonologists, and rheumatologists, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with PAH.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-113-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant from Merck & Co., Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Recommended
CME/CE MeetingPulmonary Hypertension: Diagnosis, Management, and Updates
November 16, 2024
Chicago, Illinois
1.50 credits Learn moreImplementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
CME/CEImplementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
0.25 credits
Christina Economides, MD
Brian Howard, MD
David N. Kenigsberg, MD, FACC
0.25 creditsThe Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care
The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care
CME/CE Live BroadcastThe Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care
November 16, 2024
08:00 PM - 09:30 PM PST
1.50 credits Learn more
